Review: Proteomic research in psychiatry

Journal of Psychopharmacology

Volumn 25, Issue 2, 2011, Pages 151-196

  Taurines, Regina ^a   Dudley, Edward ^a   Grassl, Julia ^b   Warnke, Andreas ^c   Gerlach, Manfred ^c   Coogan, Andrew N ^a   Thome, Johannes ^a  

^a SWANSEA UNIVERSITY   (United Kingdom)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Alzheimers disease; anxiety disorders; autism; drug addiction; mood disorders; protein profiling; proteomics; psychiatry; schizophrenia

Indexed keywords

ALZHEIMER DISEASE; AUTISM; DRUG ABUSE; HIGH THROUGHPUT SCREENING; HUMAN; MASS SPECTROMETRY; MOLECULAR GENETICS; MOOD DISORDER; NEUROPHARMACOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEOMICS; PSYCHIATRIC DIAGNOSIS; REVIEW; SCHIZOPHRENIA; ANIMAL; MENTAL DISEASE; METABOLISM; METHODOLOGY;

BIOLOGICAL MARKER;

ALZHEIMER DISEASE; ANIMALS; BIOLOGICAL MARKERS; HUMANS; MASS SPECTROMETRY; MENTAL DISORDERS; PROTEOMICS;

EID: 79551680146     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881109106931     Document Type: Review

References (210)

1. Abdi F., Quinn JF, Jankovic J., et al. (2006) Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9: 293-348.
2. Adams JD, Jr, Klaidman LK (1993) Acrolein-induced oxygen radical formation. Free Radic Biol Med 15: 187-193.
3. Aebersold R., Mann M. (2003) Mass spectrometry-based proteomics. Nature 422: 198-207.
4. Alexander-Kaufman K., James G., Sheedy D., Harper C., Matsumoto I. (2006) Differential protein expression in the prefrontal white matter of human alcoholics: A proteomics study. Mol Psychiatry 11: 56-65.
5. Beasley CL, Pennington K., Behan A., Wait R., Dunn MJ, Cotter D. (2006) Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes. Proteomics 6: 3414-3425.
6. Bierczynska-Krzysik A., Bonar E., Drabik A., et al. (2006 a) Rat brain proteome in morphine dependence. Neurochem Int 49: 401-406.
7. Bierczynska-Krzysik APradeep John JP, Silberring J., et al. (2006 b) Proteomic analysis of rat cerebral cortex, hippocampus and striatum after exposure to morphine. Int J Mol Med 18: 775-784.
8. Biser PS, Thayne KA, Fleming WW, Taylor DA (2002) Na+, K+ ATPase alpha- subunit isoform distribution and abundance in guinea-pig longitudinal muscle/myenteric plexus after exposure to morphine. Brain Res 931: 186-193.
9. Brunner J., Bronisch T., Uhr M., et al. (2005) Proteomic analysis of the CSF in unmedicated patients with major depressive disorder reveals alterations in suicide attempters. Eur Arch Psychiatry Clin Neurosci 255: 438-440.
10. Butterfield DA (2004) Proteomics: A new approach to investigate oxidative stress in Alzheimers disease brain. Brain Res 1000: 1-7.
11. Butterfield DA, Gnjec A., Poon HF, et al. (2006 a) Redox proteomics identification of oxidatively modified brain proteins in inherited Alzheimers disease: an initial assessment. J Alzheimers Dis 10: 391-397.
12. Butterfield DA, Perluigi M., Sultana R. (2006 b) Oxidative stress in Alzheimers disease brain: New insights from redox proteomics. Eur J Pharmacol 545: 39-50.
13. Butterfield DA, Sultana R. (2007) Redox proteomics identification of oxidatively modified brain proteins in Alzheimers disease and mild cognitive impairment: insights into the progression of this dementing disorder. J Alzheimers Dis 12: 61-72.
14. Carboni L., Piubelli C., Pozzato C., et al. (2006 a) Proteomic analysis of rat hippocampus after repeated psychosocial stress. Neuroscience 137: 1237-1246.
15. Carboni L., Vighini M., Piubelli C., Castelletti L., Milli A., Domenici E. (2006 b) Proteomic analysis of rat hippocampus and frontal cortex after chronic treatment with fluoxetine or putative novel antidepressants: CRF1 and NK1 receptor antagonists. Eur Neuropsychopharmacol 16: 521-537.
16. Carrette O., Demalte I., Scherl A., et al. (2003) A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimers disease. Proteomics 3: 1486-1494.
17. Carrette O., Burgess JA, Burkhard PR, et al. (2006) Changes of the cortex proteome and Apolipoprotein E in transgenic mouse models of Alzheimers Disease. J Chromatogr B Analyt Technol Biomed Life Sci 840: 1-9.
18. Carter SL, Eklund AC, Mecham BH, Kohane IS, Szallasi Z. (2005) Redefinition of Affymetrix probe sets by sequence overlap with cDNA microarray probes reduces cross-platform inconsistencies in cancer-associated gene expression measurements. BMC Bioinformatics 6: 107.
19. Castano EM, Roher AE, Esh CL, Kokjohn TA, Beach T. (2006) Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimers disease and non-demented elderly subjects. Neurol Res 28: 155-163.
20. Castegna A., Aksenov M., Aksenova M., et al. (2002 a) Proteomic identification of oxidatively modified proteins in Alzheimers disease brain. Part I: Creatine kinase BB, glutamine synthase, and ubiquitin carboxy- terminal hydrolase L-1. Free Radic Biol Med 33: 562-571.
21. Castegna A., Aksenov M., Thongboonkerd V., et al. (2002 b) Proteomic identification of oxidatively modified proteins in Alzheimers disease brain. Part II: Dihydropyrimidinase-related protein 2, alpha-enolase and heat shock cognate 71. J Neurochem 82: 1524-1532.
22. Castegna A., Thongboonkerd V., Klein JB, Lynn B., Markesbery WR, Butterfield DA (2003) Proteomic identification of nitrated proteins in Alzheimers disease brain. J Neurochem 85: 1394-1401.
23. Cecconi D., Mion S., Astner H., Domenici E., Righetti PG, Carboni L. (2007) Proteomic analysis of rat cortical neurons after fluoxetine treatment. Brain Res 1135: 41-51.
24. Chen Q., Wang S., Thompson SN, Hall ED, Guttmann RP (2006 a) Identification and characterization of PEBP as a calpain substrate. J Neurochem 99: 1133-1141.
25. Chen XL, Lu G., Gong YX, et al. (2007) Expression changes of hippocampal energy metabolism enzymes contribute to behavioural abnormalities during chronic morphine treatment. Cell Res 17: 689-700.
26. Chen Y., Bidwell LC, Norton D. (2006 b) Trait vs. state markers for schizophrenia: identification and characterization through visual processes. Curr Psychiatry Rev 2: 431-438.
27. Cheon MS, Fountoulakis M., Cairns NJ, Dierssen M., Herkner K., Lubec G. (2001) Decreased protein levels of stathmin in adult brains with Down syndrome and Alzheimers disease. J Neural Transm 61 (Suppl). 281-288. (Pubitemid 38085090)
28. Choe LH, Dutt MJ, Relkin N., Lee KH (2002) Studies of potential cerebrospinal fluid molecular markers for Alzheimers disease. Electrophoresis 23: 2247-2251.
29. Choe L., Dascenzo M., Relkin NR, et al. (2007) 8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimers disease. Proteomics 7: 3651-3660.
30. Choi J., Forster MJ, Mcdonald SR, Weintraub ST, Carroll CA, Gracy RW (2004 a) Proteomic identification of specific oxidized proteins in ApoE-knockout mice: relevance to Alzheimers disease. Free Radic Biol Med 36: 1155-1162.
31. Choi J., Levey AI, Weintraub ST, et al. (2004 b) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinsons and Alzheimers diseases. J Biol Chem 279: 13256-13264.
32. Choi J., Malakowsky CA, Talent JM, Conrad CC, Gracy RW (2002) Identification of oxidized plasma proteins in Alzheimers disease. Biochem Biophys Res Commun 293: 1566-1570.
33. Clark D., Dedova I., Cordwell S., Matsumoto I. (2006) A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry 11: 459-470.
34. Coleman PD, Flood DG (1987) Neuron numbers and dendritic extent in normal aging and Alzheimers disease. Neurobiol Aging 8: 521-545.
35. Corbett BA, Kantor AB, Schulman H., et al. (2007) A proteomic study of serum from children with autism showing differential expression of apolipoproteins and complement proteins. Mol Psychiatry 12: 292-306.
36. Cottrell BA, Galvan V., Banwait S., et al. (2005) A pilot proteomic study of amyloid precursor interactors in Alzheimers disease. Ann Neurol 58: 277-289.
37. Dascenzo M., Choe L., Lee KH (2008) iTRAQPak: An R based analysis and visualization package for 8-plex isobaric protein expression data. Brief Funct Genomic Proteomic 7: 127-135.
38. David DC, Hauptmann S., Scherping I., et al. (2005) Proteomic and functional analyses reveal a mitochondrial dysfunction in P301L tau transgenic mice. J Biol Chem 280: 23802-23814.
39. David DC, Ittner LM, Gehrig P., et al. (2006) Beta-amyloid treatment of two complementary P301L tau-expressing Alzheimers disease models reveals similar deregulated cellular processes. Proteomics 6: 6566-6577.
40. Davidson C., Gow AJ, Lee TH, Ellinwood EH (2001) Methamphetamine neurotoxicity: necrotic and apoptotic mechanisms and relevance to human abuse and treatment. Brain Res Brain Res Rev 36: 1-22.
41. Davidsson P., Gottfries J., Bogdanovic N., et al. (1999) The synaptic-vesicle-specific proteins rab3a and synaptophysin are reduced in thalamus and related cortical brain regions in schizophrenic brains. Schizophr Res 40: 23-29.
42. Davidsson P., Westman-Brinkmalm A., Nilsson CL, et al. (2002) Proteome analysis of cerebrospinal fluid proteins in Alzheimer patients. Neuroreport 13: 611-615.
43. Ding S., Dudley E., Chen L., et al. (2006) Determination of active components of Ginkgo biloba in human urine by capillary high-performance liquid chromatography/mass spectrometry with online column-switching purification. Rap. Comm. Mass Spec. 20: 3619-3624.
44. Ditzen C., Jastorff AM, Kessler MS, et al. (2006) Protein biomarkers in a mouse model of extremes in trait anxiety. Mol Cell Proteomics 5: 1914-1920.
45. Domon B., Aebersold R. (2006) Mass spectrometry and protein analysis. Science 312: 212-217.
46. Esh C., Patton L., Kalback W., et al. (2005) Altered APP processing in PDAPP (Val717 ? Phe) transgenic mice yields extended-length Abeta peptides. Biochemistry 44: 13807-13819.
47. Esterbauer H., Schaur RJ, Zollner H. (1991) Chemistry and biochemistry of 4-hydroxynonenal, malonaldehyde and related aldehydes. Free Radic Biol Med 11: 81-128.
48. Finehout EJ, Franck Z., Choe LH, Relkin N., Lee KH (2007) Cerebrospinal fluid proteomic biomarkers for Alzheimers disease. Ann Neurol 61: 120-129.
49. Finney GL, Blackler AR, Hoopmann MR, et al. (2008) Label-free comparative analysis of proteomics mixtures using chromatographic alignment of high-resolution muLC-MS data. Anal Chem 80: 961-971.
50. Forero DA, Casadesus G., Perry G., Arboleda H. (2006) Synaptic dysfunction and oxidative stress in Alzheimers disease: emerging mechanisms. J Cell Mol Med 10: 796-805.
51. Freeman WM, Brebner K., Amara SG, Reed MS, Pohl J., Phillips AG (2005) Distinct proteomic profiles of amphetamine self-administration transitional states. Pharmacogenomics J 5: 203-214.
52. Freeman WM, Hemby SE (2004) Proteomics for protein expression profiling in neuroscience. Neurochem Res 29: 1065-1081.
53. Geng T., Seitz PK, Thomas ML, et al. (2006) Use of surface enhanced laser desorption/ionization-time of flight mass spectrometry (SELDI-TOF MS) to study protein expression in a rat model of cocaine withdrawal. J Neurosci Methods 158: 1-12.
54. German DC, Gurnani P., Nandi A., et al. (2007) Serum biomarkers for Alzheimers disease: proteomic discovery. Biomed Pharmacother 61: 383-389.
55. Gillardon F., Rist W., Kussmaul L., et al. (2007) Proteomic and functional alterations in brain mitochondria from Tg2576 mice occur before amyloid plaque deposition. Proteomics 7: 605-616.
56. Godfrey AR, Williams CM, Dudley E., et al. (2009) Investigation of uremic analytes in hemodialysate and their structural elucidation from accurate mass maps generated by a multi-dimensional liquid chromatography/mass spectrometry approach. Rap. Comm. Mass Spec. 23: 3194-3204.
57. Grubb A. (1992) Diagnostic value of analysis of cystatin C and protein HC in biological fluids. Clin Nephrol 38: 20-27.
58. Gygi SP, Rochon Y., Franza BR, Aebersold R. (1999) Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19: 1720-1730.
59. Haass C., Selkoe DJ (2007) Soluble protein oligomers in neurodegeneration: Lessons from the Alzheimers amyloid beta-peptide. Nat Rev Mol Cell Biol 8: 101-112.
60. Hartman RE, Wozniak DF, Nardi A., Olney JW, Sartorius L., Holtzman DM (2001) Behavioral phenotyping of GFAP-apoE3 and -apoE4 transgenic mice: apoE4 mice show profound working memory impairments in the absence of Alzheimers-like neuropathology. Exp Neurol 170: 326-344.
61. Hegde PS, White IR, Debouck C. (2003) Interplay of transcriptomics and proteomics. Curr Opin Biotechnol 14: 647-651.
62. Hemby SE (2006) Assessment of genome and proteome profiles in cocaine abuse. Prog Brain Res 158: 173-195.
63. Ho L., Sharma N., Blackman L., Festa E., Reddy G., Pasinetti GM (2005) From proteomics to biomarker discovery in Alzheimers disease. Brain Res Brain Res Rev 48: 360-369.
64. Hoekman K., Van Nieuwkoop JA, Willemze R. (1985) The significance of beta-2 microglobulin in clinical medicine. Neth J Med 28: 551-557.
65. Hong DP, Gozu M., Hasegawa K., Naiki H., Goto Y. (2002) Conformation of beta 2-microglobulin amyloid fibrils analyzed by reduction of the disulfide bond. J Biol Chem 277: 21554-21560.
66. Hu Y., Malone JP, Fagan AM, Townsend RR, Holtzman DM (2005) Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Mol Cell Proteomics 4: 2000-2009.
67. Huang JT, Leweke FM, Oxley D., et al. (2006) Disease biomarkers in cerebrospinal fluid of patients with first-onset psychosis. PLoS Med 3: e428.
68. Huang JT, Leweke FM, Tsang TM, et al. (2007 a) CSF metabolic and proteomic profiles in patients prodromal for psychosis. PLoS ONE 2: e756.
69. Huang JT, Wang L., Prabakaran S., et al. (2007 b) Independent protein-profiling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry 13: 1118-11281.
70. Hye A., Lynham S., Thambisetty M., et al. (2006) Proteome-based plasma biomarkers for Alzheimers disease. Brain 129: 3042-3050.
71. Issaq HJ, Veenstra TD (2007) The role of electrophoresis in disease biomarker discovery. Electrophoresis 28: 1980-1988.
72. Issaq HJ, Veenstra TD, Conrads TP, Felschow D. (2002) The SELDI-TOF MS approach to proteomics: protein profiling and biomarker identification. Biochem Biophys Res Commun 292: 587-592.
73. Iwazaki T., Mcgregor IS, Matsumoto I. (2006) Protein expression profile in the striatum of acute methamphetamine-treated rats. Brain Res 1097: 19-25.
74. Jiang L., Lindpaintner K., Li HF, et al. (2003) Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia. Amino Acids 25: 49-57.
75. Johnston-Wilson NL, Sims CD, Hofmann JP, et al. The Stanley Neuropathology Consortium (2000) Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. Mol Psychiatry 5: 142-149.
76. Junaid MA, Kowal D., Barua M., et al. (2004) Proteomic studies identified a single nucleotide polymorphism in glyoxalase I as autism susceptibility factor. Am J Med Genet A 131: 11-17.
77. Kanninen K., Goldsteins G., Auriola S., Alafuzoff I., Koistinaho J. (2004) Glycosylation changes in Alzheimers disease as revealed by a proteomic approach. Neurosci Lett 367: 235-240.
78. Kapp EA, Schutz F., Connolly LM, et al. (2005) An evaluation, comparison, and accurate benchmarking of several publicly available MS/MS search algorithms: Sensitivity and specificity analysis. Proteomics 5: 3475-3490.
79. Kashem MA, James G., Harper C., Wilce P., Matsumoto I. (2007) Differential protein expression in the corpus callosum (splenium) of human alcoholics: A proteomics study. Neurochem Int 50: 450-459.
80. Khawaja X., Xu J., Liang JJ, Barrett JE (2004) Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: Implications for depressive disorders and future therapies. J Neurosci Res 75: 451-460.
81. Kidd M. (1964) Alzheimers disease-an electron microscopical study. Brain 87: 307-320.
82. Kim HG, Kim KL (2007) Decreased hippocampal cholinergic neuro-stimulating peptide precursor protein associated with stress exposure in rat brain by proteomic analysis. J Neurosci Res 85: 2898-2908.
83. Kim SH, Fountoulakis M., Cairns NJ, Lubec G. (2001) Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimers disease and Down syndrome. J Neural Transm 61 (Suppl). 223-235. (Pubitemid 38085085)
84. Kim SH, Fountoulakis M., Cairns NJ, Lubec G. (2002) Human brain nucleoside diphosphate kinase activity is decreased in Alzheimers disease and Down syndrome. Biochem Biophys Res Commun 296: 970-975.
85. Kim SH, Vlkolinsky R., Cairns N., Lubec G. (2000) Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimers disease and Down syndrome. Cell Mol Life Sci 57: 1810-1816.
86. Kim SY, Chudapongse N., Lee SM, et al. (2004) Proteomic analysis of phosphotyrosyl proteins in the rat brain: Effect of butorphanol dependence. J Neurosci Res 77: 867-877.
87. Kim SY, Chudapongse N., Lee SM, et al. (2005) Proteomic analysis of phosphotyrosyl proteins in morphinee-dependent rat brains. Brain Res Mol Brain Res 133: 58-70.
88. Korolainen MA, Auriola S., Nyman TA, Alafuzoff I., Pirttila T. (2005) Proteomic analysis of glial fibrillary acidic protein in Alzheimers disease and aging brain. Neurobio Dis 20: 858-870.
89. Korolainen MA, Goldsteins G., Alafuzoff I., Koistinaho J., Pirttila T. (2002) Proteomic analysis of protein oxidation in Alzheimers disease brain. Electrophoresis 23: 3428-3433.
90. Korolainen MA, Goldsteins G., Nyman TA, Alafuzoff I., Koistinaho J., Pirttila T. (2006) Oxidative modification of proteins in the frontal cortex of Alzheimers disease brain. Neurobiol Aging 27: 42-53.
91. Korolainen MA, Nyman TA, Nyyssonen P., Hartikainen ES, Pirttila T. (2007) Multiplexed proteomic analysis of oxidation and concentrations of cerebrospinal fluid proteins in Alzheimer disease. Clin Chem 53: 657-665.
92. Krapfenbauer K., Engidawork E., Cairns N., Fountoulakis M., Lubec G. (2003) Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res 967: 152-160.
93. Kromer SA, Kessler MS, Milfay D., et al. (2005) Identification of glyoxalase-I as a protein marker in a mouse model of extremes in trait anxiety. J Neurosci 25: 4375-4384.
94. Krueger Ddop, Wu T., Williams KR, Taylor JR, Nairn AC (2005) Proteomic Analysis of Persistent Cortico-limbic-striatal Neuroadaptions Following Repeated Cocaine Exposure in Vervet Monkeys. (online Abstract Viewer/Itinerary Planner), Washington, DC: Society for Neuroscience.
95. La Y., Wan C., Zhu H., et al. (2006) Hippocampus protein profiling reveals aberration of malate dehydrogenase in chlorpromazine/ clozapine treated rats. Neurosci Lett 408: 29-34.
96. La YJ, Wan CL, Zhu H., et al. (2007) Decreased levels of apolipoprotein A-I in plasma of schizophrenic patients. J Neural Transm 114: 657-663.
97. Lewczuk P., Esselmann H., Groemer TW, et al. (2004) Amyloid beta peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: Evidence of novel biomarkers in Alzheimers disease. Biol Psychiatry 55: 524-530.
98. Lewczuk P., Esselmann H., Meyer M., et al. (2003) The amyloid beta (Abeta) peptide pattern in cerebrospinal fluid in Alzheimers disease: Evidence of a novel carboxyterminally elongated Abeta peptide. Rapid Commun Mass Spectrom 17: 1291-1296.
99. Lewis HD, Beher D., Smith D., et al. (2004) Novel aspects of accumulation dynamics and A beta composition in transgenic models of AD. Neurobiol Aging 25: 1175-1185.
100. Lewohl JM, Van Dyk DD, Craft GE, et al. (2004) The application of proteomics to the human alcoholic brain. Ann N Y Acad Sci 1025: 14-26.
101. Li KW, Jimenez CR, Van Der Schors RC, Hornshaw MP, Schoffelmeer AN, Smit AB (2006) Intermittent administration of morphine alters protein expression in rat nucleus accumbens. Proteomics 6: 2003-2008.
102. Liao L., Cheng D., Wang J., et al. (2004) Proteomic characterisation of postmortem amyloid plaques isolated by laser capture microdissection. J Biol Chem 279: 37061-37068.
103. Liu HC, Hu CJ, Chang JG, et al. (2006) Proteomic identification of lower apolipoprotein A-I in Alzheimers disease. Dement Geriatr Cogn Disord 21: 155-161.
104. Lopez MF, Mikulskis A., Kuzdzal S., et al. (2005) High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin Chem 51: 1946-1954.
105. Lovell MA, Xie C., Markesbery WR (2001) Acrolein is increased in Alzheimers disease brain and is toxic to primary hippocampal cultures. Neurobiol Aging 22: 187-194.
106. Lubec G., Nonaka M., Krapfenbauer K., Gratzer M., Cairns N., Fountoulakis M. (1999) Expression of the dihydropyrimidinase related protein 2 (DRP-2) in Down syndrome and Alzheimers disease brain is downregulated at the mRNA and dysregulated at the protein level. J Neural Transm 57 (Suppl). 161-177.
107. Luque-Garcia JL, Neubert TA (2007) Sample preparation for serum/plasma profiling and biomarker identification by mass spectrometry. J Chromatogr A 1153: 259-276.
108. Lustbader JW, Cirilli M., Lin C., et al. (2004) ABAD directly links Abeta to mitochondrial toxicity in Alzheimers disease. Science 304: 448-452.
109. Maddalena AS, Papassotiropoulos A., Gonzalez-Agosti C., et al. (2004) Cerebrospinal fluid profile of amyloid beta peptides in patients with Alzheimers disease determined by protein biochip technology. Neurodegener Dis 1: 231-235.
110. Mayer MP, Bukau B. (2005) Hsp70 chaperones: Cellular functions and molecular mechanism. Cell Mol Life Sci 62: 670-684.
111. Mei J., Kolbin D., Kao HT, Porton B. (2006) Protein expression profiling of postmortem brain in schizophrenia. Schizophr Res 84: 204-213.
112. Melanson JE, Avery SL, Pinto DM (2006) High-coverage quantitative proteomics using amine-specific isotopic labeling. Proteomics 6: 4466-4474.
113. Mello CF, Sultana R., Piroddi M., et al. (2007) Acrolein induces selective protein carbonylation in synaptosomes. Neuroscience 147: 674-679.
114. Merchant M., Weinberger SR (2000) Recent advancements in surface-enhanced laser desorption/ionization-time of flight-mass spectrometry. Electrophoresis 21: 1164-1177.
115. Middleton FA, Mirnics K., Pierri JN, Lewis DA, Levitt P. (2002) Gene expression profiling reveals alterations of specific metabolic pathways in schizophrenia. J Neurosci 22: 2718-2729.
116. Molloy CA, Morrow AL, Meinzen-Derr J., et al. (2006) Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunol 172: 198-205.
117. Monribot-Espagne C., Boucherie H. (2002) Differential gel exposure, a new methodology for the two-dimensional comparison of protein samples. Proteomics 2: 229-240.
118. Montalto MC, Farrar G., Hehir CT (2007) Fibrillar and oligomeric beta-amyloid as distinct local biomarkers for Alzheimers disease. Ann N Y Acad Sci 1097: 239-258.
119. Moron JA, Abul-Husn NS, Rozenfeld R., Dolios G., Wang R., Devi LA (2007) Morphine administration alters the profile of hippocampal postsynaptic density-associated proteins: A proteomics study focusing on endocytic proteins. Mol Cell Proteomics 6: 29-42.
120. Moulédous L., Hunt S., Harcourt R., Harry J., Williams KL, Gutstein HB (2003) Navigated laser capture microdissection as an alternative to direct histological staining for proteomic analysis of brain samples. Proteomics 3: 610-615.
121. Moulédous L., Neasta J., Uttenweiler-Joseph S., et al. (2005) Long-term morphine treatment enhances proteasome-dependent degradation of G beta in human neuroblastoma SH-SY5Y cells: correlation with onset of adenylate cyclase sensitization. Mol Pharmacol 68: 467-476.
122. Mu J., Xie P., Yang ZS, et al. (2007) Neurogenesis and major depression: Implications from proteomic analyses of hippocampal proteins in a rat depression model. Neurosci Lett 416: 252-256.
123. Murphy GM, Jr, Lee YL, Jia XC, et al. (1995) Tumor necrosis factor-alpha and basic fibroblast growth factor decrease glial fibrillary acidic protein and its encoding mRNA in astrocyte cultures and glioblastoma cells. J Neurochem 65: 2716-2724.
124. Nathan BP, Jiang Y., Wong GK, Shen F., Brewer GJ, Struble RG (2002) Apolipoprotein E4 inhibits, and apolipoprotein E3 promotes neurite outgrowth in cultured adult mouse cortical neurons through the low-density lipoprotein receptor-related protein. Brain Res 928: 96-105.
125. Neasta J., Uttenweiler-Joseph S., Chaoui K., Monsarrat B., Meunier JC, Mouledous L. (2006) Effect of long-term exposure of SHSY5Y cells to morphine: A whole cell proteomic analysis. Proteome Sci 4: 23.
126. Nelson PG, Kuddo T., Song EY, et al. (2006) Selected neurotrophins, neuropeptides, and cytokines: Developmental trajectory and concentrations in neonatal blood of children with autism or Down syndrome. Int J Dev Neurosci 24: 73-80.
127. Nesvizhskii AI, Vitek O., Aebersold R. (2007) Analysis and validation of proteomic data generated by tandem mass spectrometry. Nat Methods 4: 787-797.
128. Newman SF, Sultana R., Perluigi M., et al. (2007) An increase in S-glutathionylated proteins in the Alzheimers disease inferior parietal lobule, a proteomics approach. J Neurosci Res 85: 1506-1514.
129. Newton JR, Parkinson D., Clench MR (2006) Strategies for examination of Alzheimers disease amyloid precursor protein isoforms. Anal Bioanal Chem 385: 692-699.
130. Newton RP, Brenton AG, Smith CJ, Dudley E. (2004) Plant proteome analysis by mass spectrometry: Principles, problems, pitfalls and recent developments. Phytochemistry 65: 1449-1485.
131. Nomura F., Tomonaga T., Sogawa K., et al. (2004) Identification of novel and down-regulated biomarkers for alcoholism by surface enhanced laser desorption/ionization-mass spectrometry. Proteomics 4: 1187-1194.
132. Novikova SI, He F., Cutrufello NJ, Lidow MS (2006) Identification of protein biomarkers for schizophrenia and bipolar disorder in the postmortem prefrontal cortex using SELDI-TOF-MS ProteinChip profiling combined with MALDI-TOF-PSD-MS analysis. Neurobiol Dis 23: 61-76.
133. Ohkubo N., Mitsuda N., Tamatani M., et al. (2001) Apolipoprotein E4 stimulates cAMP response element-binding protein transcriptional activity through the extracellular signal-regulated kinase pathway. J Biol Chem 276: 3046-3053.
134. Olausson P., Jentsch JD, Krueger DD, Tronson NC, Nairn AC, Taylor JR (2007) Orbitofrontal cortex and cognitive-motivational impairments in psychostimulant addiction: evidence from experiments in the non-human primate. Ann N Y Acad Sci 1121: 610-638.
135. Oldiges M., Lutz S., Pflug S., Schroer K., Stein N., Wiendahl C. (2007) Metabolomics: current state and evolving methodologies and tools. Appl Microbiol Biotechnol 76: 495-511.
136. Osorio C., Sullivan PM, He DN, et al. (2007) Mortalin is regulated by APOE in hippocampus of AD patients and by human APOE in TR mice. Neurobiol Aging 28: 1853-1862.
137. Pamplona R., Dalfo E., Ayala V., et al. (2005) Proteins in human brain cortex are modified by oxidation, glycoxidation, and lipoxidation. Effects of Alzheimer disease and identification of lipoxidation targets. J Biol Chem 280: 21522-21530.
138. Pan S., Rush J., Peskind ER, et al. (2008) Application of targeted quantitative proteomics analysis in human cerebrospinal fluid using a liquid chromatography matrix-assisted laser desorption/ ionization time-of-flight tandem mass spectrometer (LC MALDI TOF/TOF) platform. J Proteome Res 7: 720-730.
139. Paulson L., Martin P., Persson A., et al. (2003) Comparative genome-and proteome analysis of cerebral cortex from MK-801-treated rats. J Neurosci Res 71: 526-533.
140. Paulson L., Martin P., Ljung E., Blennow K., Davidsson P. (2004 a) Effects on rat thalamic proteome by acute and subchronic MK-801-treatment. Eur J Pharmacol 505: 103-109.
141. Paulson L., Martin P., Ljung E., Blennow K., Davidsson P. (2007) Proteome analysis after co-administration of clozapine or haloperidol to MK-801-treated rats. J Neural Transm 114: 885-891.
142. Paulson L., Martin P., Nilsson CL, et al. (2004 b) Comparative proteome analysis of thalamus in MK-801-treated rats. Proteomics 4: 819-825.
143. Paulson L., Persson R., Karlsson G., et al. (2005) Proteomics and peptidomics in neuroscience. Experience of capabilities and limitations in a neurochemical laboratory. J Mass Spectrom 40: 202-213.
144. Pennington K., Beasley CL, Dicker P., et al. (2007) Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 13: 1102-1117.
145. Prabakaran S., Swatton JE, Ryan MM, et al. (2004) Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9: 684-697. (Pubitemid 38932173)
146. Prabakaran S., Wengenroth M., Lockstone HE, Lilley K., Leweke FM, Bahn S. (2007) 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J Proteome Res 6: 141-149.
147. Prokai L., Zharikova AD, Stevens SM, Jr (2005) Effect of chronic morphinee exposure on the synaptic plasma-membrane subproteome of rats: A quantitative protein profiling study based on isotope-coded affinity tags and liquid chromatography/mass spectrometry. J Mass Spectrom 40: 169-175.
148. Puchades M., Hansson SF, Nilsson CL, Andreasen N., Blennow K., Davidsson P. (2003) Proteomic studies of potential cerebrospinal fluid protein markers for Alzheimers disease. Brain Res Mol Brain Res 118: 140-146.
149. Ramassamy C., Averill D., Beffert U., et al. (1999) Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimers disease is related to the apolipoprotein E genotype. Free Radic Biol Med 27: 544-553.
150. Ray S., Britschgi M., Herbert C., et al. (2007) Classification and prediction of clinical Alzheimers diagnosis based on plasma signaling proteins. Nature Med 13: 1359-1362.
151. Roth M., Tomlinson BE, Blessed G. (1966) Correlation between scores for dementia and counts of senile plaques in cerebral grey matter of elderly subjects. Nature 209: 109-110.
152. Ru QC, Zhu LA, Silberman J., Shriver CD (2006) Label-free semiquantitative peptide feature profiling of human breast cancer and breast disease sera via two-dimensional liquid chromatographymass spectrometry. Mol Cell Proteomics 5: 1095-1104.
153. Schenk D., Barbour R., Dunn W., et al. (1999) Immunization with Abeta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400: 173-177.
154. Schlicht K., Buttner A., Siedler F., et al. (2007) Comparative proteomic analysis with postmortem prefrontal cortex tissues of suicide victims versus controls. J Psychiatr Res 41: 493-501.
155. Schonberger SJ, Edgar PF, Kydd R., Faull RL, Cooper GJ (2001) Proteomic analysis of the brain in Alzheimers disease: Molecular phenotype of a complex disease process. Proteomics 1: 1519-1528.
156. Schwarz MJ, Riedel M., Gruber R., Muller N., Ackenheil M. (1998) Autoantibodies against 60- kDA heat shock protein in schizophrenia. Eur Arch Psychiatry Clin Neurosci 248: 282-288.
157. Schwarz E., Levin Y., Wang L., Leweke FM, Bahn S. (2007) Peptide correlation: a means to identify high quality quantitative information in large-scale proteomic studies. J Sep Sci 30: 2190-2197.
158. Selenica ML, Wang X., Ostergaard-Pedersen L., Westlind-Danielsson A., Grubb A. (2007) Cystatin C reduces the in vitro formation of soluble Abeta1-42 oligomers and protofibrils. Scand J Clin Lab Invest 76: 179-190.
159. Sergeant N., Bombois S., Ghestem A., et al. (2003) Truncated beta-amyloid peptide species in pre-clinical Alzheimers disease as new targets for the vaccination approach. J Neurochem 85: 1581-1591.
160. Sharma SK, Nirenberg M., Klee WA (1975) Morphine receptors as regulators of adenylate cyclase activity. Proc Natl Acad Sci U S A 72: 590-594.
161. Sharp FR, Jasper P., Hall J., Noble L., Sagar SM (1991) MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex. Ann Neurol 30: 801-809.
162. Shin SJ, Lee SE, Boo JH, et al. (2004) Profiling proteins related to amyloid deposited brain of Tg2576 mice. Proteomics 4: 3359-3368.
163. Simonsen AH, Hansson SF, Ruetschi U., et al. (2007 a) Amyloid beta1-40 quantification in CSF: Comparison between chromatographic and immunochemical methods. Dement Geriatr Cogn Disord 23: 246-250.
164. Simonsen AH, Mcguire J., Hansson O., et al. (2007 b) Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch Neurol 64: 366-370.
165. Simonsen AH, Mcguire J., Podust VN, et al. (2007 c) Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimers disease. Neurobiol Aging 29 (7). 961-968.
166. Simonsen AH, Mcguire J., Podust VN, et al. (2007 d) A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimers disease versus normal aging and frontotemporal dementia. A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimers disease versus normal aging and frontotemporal dementia dement Geriatr Cogn 24: 434-440.
167. Sizova D., Charbaut E., Delalande F., et al. (2006) Proteomic analysis of brain tissue from an Alzheimers disease mouse model by two-dimensional difference gel electrophoresis. Neurobiol Aging 28: 357-370.
168. Sjogren M., Blennow K. (2005) The link between cholesterol and Alzheimers disease. World J Biol Psychiatry 6: 85-97.
169. Sogawa K., Itoga S., Tomonaga T., Nomura F. (2007) Diagnostic values of surface-enhanced laser desorption/ionization technology for screening of habitual drinkers. Alcohol Clin Exp Res 31: 22-26.
170. Soreghan BA, Lu BW, Thomas SN, et al. (2005) Using proteomics and network analysis to elucidate the consequences of synaptic protein oxidation in a PS1 + AbetaPP mouse model of Alzheimers disease. J Alzheimers Dis 8: 227-241.
171. Squier TC (2001) Oxidative stress and protein aggregation during biological aging. Exp Gerontol 36: 1539-1550.
172. Sullivan PF, Fan C., Perou CM (2006) Evaluating the comparability of gene expression in blood and brain. Am J Med Genet B Neuropsychiatr Genet 141: 261-268.
173. Sultana R., Boyd-Kimball D., Poon HF, et al. (2006 a) Oxidative modification and down-regulation of Pin1 in Alzheimers disease hippocampus: A redox proteomics analysis. Neurobiol Aging 27: 918-925.
174. Sultana R., Boyd-Kimball D., Poon HF, et al. (2006 b) Redox proteomics identification of oxidized proteins in Alzheimers disease hippocampus and cerebellum: An approach to understand pathological and biochemical alterations in AD. Neurobiol Aging 27: 1564-1576.
175. Sultana R., Newman SF, Abdul HM, et al. (2006 c) Protective effect of D609 against amyloid-beta1-42-induced oxidative modification of neuronal proteins: redox proteomics study. J Neurosci Res 84: 409-417.
176. Sultana R., Perluigi M., Butterfield DA (2006 d) Redox proteomics identification of oxidatively modified proteins in Alzheimers disease brain and in vivo and in vitro models of AD centered around Abeta(1-42). J Chromatogr B Analyt Technol Biomed Life Sci 833: 3-11.
177. Sultana R., Poon HF, Cai J., et al. (2006 e) Identification of nitrated proteins in Alzheimers disease brain using a redox proteomics approach. Neurobiol Dis 22: 76-87.
178. Sultana R., Reed T., Perluigi M., Coccia R., Pierce WM, Butterfield DA (2007) Proteomic identification of nitrated brain proteins in amnestic mild cognitive impairment: A regional study. J Cell Mol Med 11: 839-851. (Pubitemid 47313301)
179. Tamminga CA, Holcomb HH, Gao XM, Lahti AC (1995) Glutamate pharmacology and the treatment of schizophrenia: Current status and future directions. Int Clin Psychopharmacol 10: 29-37.
180. Tang K., Page JS, Smith RD (2004) Charge competition and the linear dynamic range of detection in electrospray ionization mass spectrometry. J Am Soc Mass Spectrom 15: 1416-1423.
181. Tannu N., Mash DC, Hemby SE (2007) Cytosolic proteomic alterations in the nucleus accumbens of cocaine overdose victims. Mol Psychiatry 12: 55-73.
182. Tannu NS, Hemby SE (2006) Methods for proteomics in neuroscience. Prog Brain Res 158: 41-82.
183. Taurines R., Dudley E., Conner AC, et al. (2009) Serum protein profiling and proteomics in autistic spectrum disorder using magnetic bead-assisted mass spectrometry. Eur Arch Psychiatry Clin Neurosci. (In Press).
184. Todtenkopf MS, Stellar JR, Williams EA, Zahm DS (2004) Differential distribution of parvalbumin immunoreactive neurons in the striatum of cocaine sensitized rats. Neuroscience 127: 35-42.
185. Tsuji T., Shimohama S. (2001) Analysis of the proteomic profiling of brain tissue in Alzheimers disease. Dis Markers 17: 247-257.
186. Tsuji T., Shiozaki A., Kohno R., Yoshizato K., Shimohama S. (2002) Proteomic profiling and neurodegeneration in Alzheimers disease. Neurochem Res 27: 1245-1253.
187. Unlu M., Morgan ME, Minden JS (1997) Difference gel electrophoresis: A single gel method for detecting changes in protein extracts. Electrophoresis 18: 2071-2077.
188. Vawter MP, Ferran E., Galke B., Cooper K., Bunney WE, Byerley W. (2004) Microarray screening of lymphocyte gene expression differences in a multiplex schizophrenia pedigree. Schizophr Res 67: 41-52.
189. Vehmas AK, Borchelt DR, Price DL, et al. (2001) beta-Amyloid peptide vaccination results in marked changes in serum and brain Abeta levels in APPswe/PS1DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip technology. DNA Cell Biol 20: 713-721.
190. Vercauteren FG, Bergeron JJ, Vandesande F., Arckens L., Quirion R. (2004 a) Proteomic approaches in brain research and neuropharmacology. Eur J Pharmacol 500: 385-398.
191. Vercauteren FG, Clerens S., Roy L., et al. (2004 b) Early dysregulation of hippocampal proteins in transgenic rats with Alzheimers disease-linked mutations in amyloid precursor protein and presenilin 1. Brain Res Mol Brain Res 132: 241-259.
192. Vercauteren FG, Flores G., Ma W., et al. (2007) An organelle proteomic method to study neurotransmission-related proteins, applied to a neurodevelopmental model of schizophrenia. Proteomics 7: 3569-3579.
193. Vermuyten K., Lowenthal A., Karcher D. (1990) Detection of neuron specific enolase concentrations in cerebrospinal fluid from patients with neurological disorders by means of a sensitive enzyme immunoassay. Clin Chim Acta 187: 69-78.
194. von Haller PD, Yi E., Donohoe S., et al. (2003) The application of new software tools to quantitative protein profiling via isotope-coded affinity tag (ICAT) and tandem mass spectrometry: II. Evaluation of tandem mass spectrometry methodologies for large-scale protein analysis, and the application of statistical tools for data analysis and interpretation. Mol Cell Proteomics 2: 428-442.
195. Wan C., La Y., Zhu H., et al. (2007) Abnormal changes of plasma acute phase proteins in schizophrenia and the relation between schizophrenia and haptoglobin (Hp) gene. Amino Acids 32: 101-108.
196. Wan C., Yang Y., Li H., et al. (2006) Dysregulation of retinoid transporters expression in body fluids of schizophrenia patients. J Proteome Res 5: 3213-3216.
197. Wang Q., Woltjer RL, Cimino PJ, et al. (2005) Proteomic analysis of neurofibrillary tangles in Alzheimer disease identifies GAPDH as a detergent-insoluble paired helical filament tau binding protein. FASEB J 19: 869-871.
198. Wiese S., Reidegeld KA, Meyer HE, Warscheid B. (2007) Protein labeling by iTRAQ: a new tool for quantitative mass spectrometry in proteome research. Proteomics 7: 340-350.
199. Woltjer RL, Cimino PJ, Boutte AM, et al. (2005) Proteomic determination of widespread detergent-insolubility including Abeta but not tau early in the pathogenesis of Alzheimers disease. FASEB J 19: 1923-1925.
200. Wong EH, Kemp JA, Priestley T., Knight AR, Woodruff GN, Iversen LL (1986) The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci U S A 83: 7104-7108.
201. Yang L., Sun ZS, Zhu YP (2007) Proteomic analysis of rat prefrontal cortex in three phases of morphine-induced conditioned place preference. J Proteome Res 6: 2239-2247.
202. Yang Y., Wan C., Li H., et al. (2006) Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal Chem 78: 3571-3576.
203. Yao JK, Reddy R., Van Kammen DP (2000) Abnormal age-related changes of plasma antioxidant proteins in schizophrenia. Psychiatry Res 97: 137-151.
204. Yeom M., Shim I., Lee HJ, Hahm DH (2005) Proteomic analysis of nicotine-associated protein expression in the striatum of repeated nicotine-treated rats. Biochem Biophys Res Commun 326: 321-328.
205. Yoo BC, Cairns N., Fountoulakis M., Lubec G. (2001 a) Synaptosomal proteins, beta-soluble N-ethylmaleimide-sensitive factor attachment protein (beta-SNAP). gamma-SNAP and synaptotagmin I in brain of patients with Down syndrome and Alzheimers disease. Dement Geriatr Cogn Disord 12: 219-225.
206. Yoo BC, Kim SH, Cairns N., Fountoulakis M., Lubec G. (2001 b) Deranged expression of molecular chaperones in brains of patients with Alzheimers disease. Biochem Biophys Res Commun 280: 249-258. (Pubitemid 32917504)
207. Yu HL, Chertkow HM, Bergman H., Schipper HM (2003) Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics 3: 2240-2248.
208. Zhang J., Goodlett DR, Quinn JF, et al. (2005) Quantitative proteomics of cerebrospinal fluid from patients with Alzheimer disease. J Alzheimers Dis 7: 125-133 (discussion 173-180 ).
209. Zhang J., Montine TJ (2007) Proteomic discovery of CSF biomarkers for Alzheimers disease. Ann Neurol 61: 497 ; author reply 497-498.
210. Zimmerman AW, Jyonouchi H., Comi AM, et al. (2005) Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol 33: 195-201.